Previous Awards

Pawel Swietach, Department of Physiology, Anatomy and Genetics 
Do mutations in SLC4A3 expose a druggable vulnerability in the adaptation of endometrial cancer to hypoxia?

Valentine Macaulay, Jinseon (Selena) Kim, Nuffield Department of Surgical Sciences
The WINGMEN trial: investigating effects of IGF blockade on the tumour immune microenvironment of localised prostate cancer

Anna Rose, Department of Paediatrics
Exploiting FAM111A protease to selectively target ALT cancers

Berna Bou Tayeh, Yang Shi, Ludwig Institute for Cancer Research 
Unveiling the epigenetic regulators of Natural Killer cell exhaustion and their use for cancer immunotherapy

Keaton Jones, Nuffield Department of Surgical Sciences 

High Intensity Focused Ultrasound (HIFU) as an immune primer in pancreatic cancer

Eileen Parkes, Department of Oncology 

Immunosuppression in oesophageal adenocarcinoma

Olaf Ansorge, Nuffield Department of Clinical Neurosciences
Novel Analytical Technologies for Precision Medicine in Rare Sarcomas – A Pilot Study on Mesenchymal Chondrosarcoma

Adam Wilkinson & Yavor Bozhilov, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine 
Investigating the functional consequences of gaining chromosomes inhuman blood stem cells

Lennard Lee, David Anaya, Tim Elliott, Rob Watson, Miles Weatherseed, Nuffield Department of Medicine 
The Oxford Cancer Vaccine Project Mouse POEM pioneer study

Clive Wilson, Francesca Buffa & Chris Cunningham, Department of Physiology Anatomy & Genetics
Functional analysis of the sumoylation-dependent miRNA transcriptome in pro-tumorigenic Rab11a-exosomes

Alex Gordon-Weeks et al., Nuffield Department of Surgical Sciences
Targeting LOXL2 Activity to Alter Extracellular Matrix Structure and Promote Immune Checkpoint Sensitivity in Colorectal Cancer

John Parrington & Colin Goding, Department of Pharmacology
The roles and mechanisms of action of the two-pore channels TPC1 and TPC2 in melanoma tumourigenesis and metastasis

Diana Withrow & Brian Nicholson, Department of Primary Health Care Sciences
Exploring morbidity among long-term survivors of non-malignant meningioma

Matthias Friedrich et al., Nuffield Department of Medicine Translational Gastroenterology Unit
Validation of a core membrane marker set for reliable cell segmentation analysis across different multiplex imaging platforms

Niamh Appleby, Calliope Dendrou & Anna Schuh, Department of Oncology Oxford Molecular Diagnostic Centre
Comprehensive multi-modal assessment of early B-cell neoplasms: A pilot collaboration between OXPLORED and CARTOGRAPHY

Benjamin Fairfax, Eleni Ieremia & Alistair Easton, Department of Oncology 
Examining the relationship between tertiary lymphoid structures within primary melanomas and the systemic response to Immune Checkpoint Blockade

Eoghan J Mulholland, Wellcome Centre for Human Genetics
Development of a Bespoke Multiplex panel for the detection of CAF subtypes in Colorectal Cancer

Doreen Lau, Tim Elliott & Bart Cornelissen, Nuffield Department of Medicine Target Discovery Institute
Molecular Imaging of Antigen-specific T cells in Cancer Immunotherapy

Karl Morten et al., Nuffield Department of Women’s and Reproductive Health
Developing Raman micro-spectroscopy to determine the OXPHOS/glycolysis status of patient tumours.

Simon Buczacki, Nikhil Lal & Minn-E Ng, Nuffield Department of Surgical Sciences
Linking Paneth cell differentiation and T-cell activation in colon cancer organoid cultures

Romuald Binet, Kristijan Ramadan & Davide Mazza, Ludwig Institute for Cancer Research
Deciphering the interaction between MITF and the MRE11-NBS1-RAD50 complex – a melanoma-specific regulation of the DNA Damage response

Tom Agnew, Sir William Dunn School of Pathology
ARH3 as a potential new biomarker in breast, ovarian and pancreatic and prostate cancer

Elizabeth Mann et al., The Kennedy Institute of Rheumatology, NDORMS
Ex vivo phenotyping of Th17 cells from colorectal cancer patients

Kourosh Honarmand Ebrahimi & James McCullagh, Department of Chemistry, Chemistry Research Laboratory
Metabolomics investigation of an emerging immunometabolic pathway linking viral infection and inflammation to cancer

Linna Zhou, The Ludwig Institute & Department of Chemistry
Engineered gastrointestinal tissues to investigate the influence of enteric neurons in cancer progression

Mariolina Salio & Graham Collins, Human Immunology Unit & Department of Haematology, Oxford University Hospitals
Immune microenvironment signatures predictive of response in patients with classical Hodgkin Lymphoma treated with checkpoint inhibitors

Karthik Ramasamy & Ross Sadler, Department of Haematology, Oxford University Hospitals & Nuffield Department of Medicine
Post translational modification of free light chains as a biomarker for progression from monoclonal gammopathy of undetermined significance to myeloma

Monica Olcina et al., MRC Oxford Institute for Radiation Oncology, Department of Oncology
C5aR1 as a biomarker in ovarian cancer – Towards the development of radioligands for imaging and therapy of C5aR1 expressing tumours

Ricardo Fernandes, Nuffield Department of Medicine
Development of a new approach to target FLT3 signalling in AML

Simon Carr & Wojciech Barczak, Department of Oncology
Tumour specific neo-antigens derived from the non-coding genome

Andrew Blackford, Department of Oncology
Characterising short linear peptide motifs in tumour suppressor proteins

Thomas Lanyon-Hogg, Department of Pharmacology
Development of novel Hedgehog acyltransferase inhibitors from HTS hits to lead series

Val Macaulay, Ian Mills & Jack Mills, Department of Oncology & Nuffield Department of Surgical Sciences
Investigating nuclear IGF-1R function in clinical prostate cancers

Wayne Paes et al., Centre for Cellular and Molecular Physiology, Nuffield Department of Medicine
Empirical determination of molecular biomarkers for precision-based immunotherapy in colorectal cancer

Shijie Cai et al., Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine
Identification of small molecule inhibitors and synthetic lethality for GTP cyclohydrolase in triple-negative breast cancer

Ms Marketa Tomkova & Mr Michael McClellan Ludwig Cancer Research

Detection of non-clonal mutations and mutational signatures by single-molecule sequencing

Ms Yurena Vivas-García Ludwig Institute for Cancer Research, Nuffield Department of Medicine

Identification of pathways driving resistance to drugs targeting fatty acid saturation in cancer

Prof Simon Leedham & Ms Nadia Nasreddin Nuffield Department of Medicine

The WNT signalling pathway landscape of colitis-associated colorectal cancer

Ms Mara Artibani Nuffield Department of Women’s and Reproductive Health / Weatherall Institute of Molecular Medicine

Establishing a 3D model of minimal residual disease for drug screening

Prof Matthew Freeman Sir Dunn School of Pathology

Developing animal models of iRhom2, a potential new target in KRAS-induced cancer

Dr Lonnie Swift Department of Oncology

Exploiting synthetic defects in metabolism and DNA repair to improve the treatment of glioma

Prof Geoff Higgins Department of Oncology

Preclinical evaluation of Atovaquone as an immune therapy sensitiser

Prof Richard Gibbons Radcliffe Department of Medicine /Nuffield Division of Clinical Laboratory Sciences /WIMM Weatherall Institute of Molecular Medicine

Genome-wide optical mapping of replication stalling

Ms Ysobel Baker & Prof Tom Brown Department of Chemistry

New chemical architectures for the therapeutic targeting of RNA

Dr Benjamin Fairfax Department of Oncology

Characterising the cfDNA methylome in patients with metastatic melanoma treated with immune checkpoint blockade

Dr Lynn Quek, MRC MHU, Weatherall Institute of Molecular Medicine

Single cell transcriptomic and proteomic analysis of granulocyte-monocyte and erythroid differentiation in normal haematopoietic progenitors and in Acute Myeloid Leukaemia.

Dr Gillian Farnie, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences

Investigating tumour heterogeneity to discover mechanisms of inherent and therapy induced resistance

Prof. Anne Kiltie, CRUK/MRC Oxford Institute of Radiation Oncology

Development of a human gastrointestinal epithelial organoid assay to identify non-toxic chemoradiation combinations for abdominal and pelvic tumours

Dr Shivan Sivakumar, Department of Oncology

Mapping the T cell architecture of pancreatic cancer

Dr Natalia Gromak, Sir William Dunn School of Pathology

Molecular Mechanism of APOBEC3B-Dependent targeting of pathological R loops in breast cancer

Dr Benjamin Schuester-Bockler, Nuffield Department of Medicine, Big Data Institute 

Determining the mechanism of mutagenesis in gastric and oesophageal adenocarcinomas

Dr Jacqueline Boultwood, Nuffield Division of Clinical Laboratory Sciences

Single-cell analysis of haematopoietic stem cells in advanced myelodysplastic syndromes: identification of new therapeutic treatments/targets

Dr Jordan Becker, Wellcome Centre for Human Genetics 

Dissecting the mechanism of BRCA1-BARD1 complex function in DNA double-strand break repair

Dr Jan Bornschein, Translational Gastroenterology Unit

Transcriptome profiling of different stages of inflammatory, preneoplastic, and neoplastic alterations of the gastric mucosa by RNA-sequencing. Analysis of risk-factor associated gene expression signatures and virtual microdissection to enable analysis of epithelial-stromal interaction.

Dr Fumiko Esahi, Sir William Dunn School of Pathology

Exploring the role of BRCA1 AND PALB2 in myeloid differentiation

Prof Sarah Blagden, Department of Oncology

The Role of Olaparib and PARPs in the Cellular Stress Response

Dr Jakub Kopycinski, Nuffield Department of Medicine

Use of High-Definition immune profiling to understand mechanisms underpinning control of high-risk Human Papillomavirus (hrHPV) in exposed women.

Dr Dawn O’Reilly, Department of Oncology

Examine the feasibility of long-range sequencers to build a comprehensive transcriptome isoform blueprint of human breast cancer cells– “a proof of concept” study.

Dr Michael Tellier, Sir William Dunn School of Pathology

Understanding the function of the cyclin-dependent kinase 10 (CDK10) and cyclin M (CycM) in cancer and STAR syndrome, a developmental genetic disease

Prof Ahmed Ahmed, Nuffield Department of Women’s & Reproductive Health

Molecular validation of a putative novel aggressive molecular subtype of ovarian cancer

Brian Lyons, Department of Oncology
Use of a mirror image D-amino acid peptide shield to induce immune silencing of an oncolytic virus rendering it hidden to pre-existing neutralising antibodies thus increasing bio-availability and therapeutic efficacy

Abirami Lakshminarayanan, Radiobiology Research Institute, Department of Oncology
Antibody fragments as next generation imaging probes for radiation therapy

Felix Clanchy, Kennedy Institute of Rheumatology
How do IRAK-3 Isoforms contribute to tumour progression?

Akane Kawamura, Department of Chemistry
Targeting the NSD family protein methyltransferases for cancer treatment

Lisa Heather, Department of Physiology, Anatomy and Genetics
Fatty acids as novel metabolic regulators of HIF signalling and hypoxic sensitivity in cancer

Fiona Bangs, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology and The Kennedy Institute of Rheumatology
The impact of the primary cilium on initiation and progression of pancreatic ductal adenocarcinoma

Serena Lucotti, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology
Targeting tumour cell transendothelial migration during metastasis

Richard Bryant, Nuffield Department of Surgical Sciences
Transcriptomics of pre-radiotherapy prostate cancer biopsy samples – a “proof-of-concept” study

Audrey Gerard, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences and The Kennedy Institute of Rheumatology
Increasing cancer vaccine efficacy through temporal blockade of IFNg

Peter Holland, Department of Zoology
Assessment of novel Testicular Germ Cell Tumour markers

Adam Cribbs, Botnar Research Centre – Oxford Centre for Translational Myeloma Research
Identifying epigenetic targets to modulate immune checkpoints in the treatment of multiple myeloma

Tim Humphrey, CRUK-MRC Oxford Institute for Radiation Oncology, Department of Oncology
Binding partners and imaging of the p53-targeting agent RITA

Simon Aldridge, Department of Chemistry
Novel boron-containing 18F tags for PET and bimodal imaging

Hagen Schwenzer, Department of Oncology
Exploring LARP6 as new potential drug target to treat HER2-negative gastric cancer

Dr Viktor H. Koelzer, Wellcome Trust Centre for Human Genetics
Prof Tim Maughan, CRUK/MRC Oxford Institute for Radiation Oncology
Expression and polymorphisms of the pattern recognition receptors Stimulator of Interferon Genes (STING) and Toll-like Receptor (TLR) 4 as predictors of disease free survival in the Short Course Oncology Treatment (SCOT) trial of stage II-III colorectal cancer patients.

Mr Puneet Plaha, Oxford University Hospitals NHS Foundation Trust
Mr James Livermore, Department of Neurosurgery
Using night vision goggles to increase the precision of brain tumour surgery

Dr Bart Cornelissen, Department of Oncology
Peptide radionuclide imaging and therapy for pancreatic neuroendocrine tumours

Dr Heidi Olzscha, Department of Oncology
Characterisation of the citrullinome in malignant cell model systems

Dr Alvina G Lai, Professor Jane A McKeating, Target Discovery Institute, Nuffield Department of Medicine
Hypoxic-gene signatures in hepatitis B virus infection that predict hepatocellular carcinoma progression

Dr Vincenzo D’Angiolella, Department of Oncology
A system wide approach to investigate the role of deoxyribonucleotides (dNTPs) in genome stability and cancer cell survival

Dr Richard Owen, Ludwig Cancer Research
An integrative analysis of genomic, proteomic and histology image features in oesophageal metaplasia, dysplasia, and adenocarcinoma.

Dr Enric Domingo, Department of Oncology
Assessment of formalin-fixed paraffin embedded DNA for genome-wide associations studies

Dr Joshua W Owen, IBME
The development of oxygen loaded nanodroplets designed to deliver oxygen under the application of ultrasound for the treatment of tumour hypoxia.

Dr Ole Tietz, Department of Oncology
Intracellular targeting of cancer testis antigens (CTAs) using multimeric cell penetrating peptide (CPPs) clusters

Dr John Jacob, Clinical Neuroscience
Dr Vincenzo D’Angiolella, Dr Frances Willenbrock, Oncology
Resolving the significance and mechanism of altered cholesterol metabolism in sonic hedgehog driven medulloblastoma

Prof Catherine Green, WTCHG
SetD3 as a novel target for cancer therapeutics

Prof Alison Banham, NDCLS
Dr Daniel Ebner, TDI
CRISPR Whole Genome Screen to Identify Pathways Driving Expression of the FOXP1 Oncogene

Dr Jia-Ling Ruan, Prof Anne Kiltie, Oncology
Immunomodulation by Gemcitabine-Based Chemoradiation Therapy in Muscle Invasive Bladder Cancer

Prof Simon Leedham, WTCHG
Using somatic mutation to reflect variable underlying disease pathogenesis in colorectal cancer

Dr Imre Mäger, DPAG
The proteome and brain microvascular endothelial cell interactions of brain-metastatic breast cancer extracellular vesicles

Prof Shona Murphy, Dr Justyna Zaborowska, Dunn School
CDK12 at the front line of the DNA Damage Response

Dr Bart Cornelissen, Oncology
Discovery of novel targets to image the effects of irradiation

Dr Gillian Farnie, NDORMS
Prof Claire Edwards, NDS
The influence of bone marrow adipocytes on the activity and dormancy of breast cancer metastasis

Dr Jurgen Brem, Chemistry
Dynamic combinatoria chemistry to develop novel anticancer agents

Prof Panagis Filippakopoulos, SGC
Prof Eric O’Neil, Oncology
Prof Tom Milne, Wimm
BRD4-directed recruitment of NuRD as a potential therapeutic target in cancer

Dr Johanna Michl, Prof Madalena Tarsounas, Oncology
Developing inhibitors of the Fanconi anemia pathway for the treatment of BRCA1/2-deficient cancers

Prof Adam Mead, WIMM
Measuring DNA Damage in Single Cells Using a Novel High Throughput Genomic Assay

Dr Nick Coupe, Oncology
In Vivo investigation of the orphan receptor ROR2 in angiogenesis and bevacizumab sensitivity in BRAF mutant melanoma

Dr Alfredo Castello Palomares, Biochemistry
Decoding the role of the RNA binding activity of p53

Prof Ian Tomlinson, Dr Lennard Lee, WTCHG
Colorectal cancer metastasis signatures and immune profiling of the lymphoid niche – predicting tumour recurrence

Dr Nicola Farrer, Chemistry
Ultrasonic Delivery of Pt(IV) Prodrugs

Dr Annabelle Lewis, Dr Roland Arnold, WTCHG
Identification of drivers of colon cancer cell differentiation: using a validated genomewide CRISPR transcriptional activation screen.

Dr Yanyan Jiang, Dr Anderson Ryan, Oncology
Targeting DNA-PK to selectively potentiate radiosensitivity in a xenograft model of lung cancer by contextual synthetic lethality

Dr Bilyana Stoilova, Prof Paresh Vyas, MHU
Determining the heterogeneity of progenitor phenotypes in human Acute Myeloid Leukaemia

Prof Nicholas La Thangue, Dr Rebecca Miller, Oncology
Dr Weston Struwe, Glycobiology
Heparin sulfate oligosaccharides that bind and inhibit tumourigenic growth have potential as drugs to limit glioma progression

Dr Anjali Kusumbe, Kennedy
Regulation of breast cancer cell metastasis by distinct blood vessel subtypes in the bone marrow microenvironment

Dr Tom McAllister, Dr Akane Kawamura, Chemistry
Cyclic Peptides inhibitors of the IGF/IGF-1R Interaction

Prof Ahmed Ahmed, NDOG
Targeting FER for the treatment of ovarian cancer

Prof Kristijan Ramadan, Department of Oncology
Characterization of the SPRTN metalloprotease in DNA-protein crosslinks repair and its potential for cancer therapy

Dr Andrew Protheroe, OUH NHS Foundation Trust
Dr Kilian Huber, SGC
Chemical proteomics to define the kinome of renal cancer and investigate resistance mechanisms to kinase inhibitors

Dr Victor Bolanos-Garcia, Oxford Brookes University
Prof Paul Brennan, SGC
New anticancer therapies through inhibitiion of Anaphase Promoting complex/cyclosome (APC/C) activation by Cdc20

Prof Paul Fairchild, Dunn School of Pathology
Exploiting the epigenetic memory of iPS cells to optimise dendritic cell based vaccinesNew anticancer therapies through inhibitiion of Anaphase Promoting complex/cyclosome (APC/C) activation by Cdc20

Dr Barbara Braden, OUH NHS Foundation Trust
Computer-aided recognition of Barrett’s oesophagus and its early neoplastic changes

Dr Thomas Ashton, Department of Oncology
Study of the anti-malarial, Atovaquone, as an anti-cancer therapeutic

Dr Dimitris Karamitros, MRC Molecular Hematology Unit
Implementation of novel xenotransplantation mouse models for study of human AML LSC

Dr Pavitra Kannan, Dr Benjamin Irving, Department of Oncology
Linking functional MRI with 3D microscopy to assess radiotherapy response in tumour subregions

Prof Deborah Goberdhan, DPAG
Prof Tudor Fulga, WIMM
Proteome and transcriptome of stress-induced cancer exosomes

Dr Ian Gibbs-Seymour, Dunn School of Pathology
Generation of tools to assess a potential new biomarker in breast, ovarian and prostate cancer tissues

Dr Jyothi Menon, Prof Kate Vallis, Department of Oncology
Prof Robert Carlisle, IBME
Ultrasound-responsive nanocomposite hydrogels for treatment of localised chest wall cancer recurrence

Dr Margaret Duffy, Prof Len Seymour, Department of Oncology
Establishing an ex vivo culture platform for slices from freshly-resected human tumours

Dr Jadwiga Nieminuszczy, Department of Oncology
Biochemical characterisation of a novel exonuclease required for homologous recombination as potential target for improving cancer therapy

Prof Shoumo Bhattacharya, Cardiovascular Medicine
Targeting the chemokine system in breast and metastatic colon cancer using novel Evasins identified from tick saliva

Prof Colin Goding, Ludwig Cancer Research

Prof Sarah Blagden, Department of Oncology
Translation reprogramming as a therapeutic target in cancer

Dr Bart Cornelissen, Department of Oncology

Prof Veronique Gouverneur, Department of Chemistry
PET Imaging with PARP inhibitors

Dr Oleg Fedorov, Prof Paul Brennan, SGC

Prof Udo Oppermann, NDORMS
Towards development of histone methyl-lysine reader inhibitors for SPIN1- a novel molecular target in liposarcoma

Prof Udo Oppermann, NDORMS

Dr Karthik Ramasamy,  OUH NHS Foundation Trust
Tool development to monitor immune suppressive mechanisms by epigenetic inhibitors in multiple myeloma

Dr James Larkin, Prof Nicola Sibson, Department of Oncology
Metabolomic identification of melanoma and lung cancer patients with brain metastases

Dr Simon Lord, OUH NHS Foundation Trust

Dr Neel Patel, OUH NHS Foundation Trust

Dr Anderson Ryan, Department of Oncology
Repurposing cardiac perfusion imaging as a biomarker of anti-angiogenic and antimitochondrial therapy

Dr Benoit Van den Eynde, Ludwig Cancer Research
Developing viral vectored vaccines for MAGE-expressing tumours

Prof Nicholas Lakin, Department of Biochemistry
Identifying novel applications for the use of PARP inhibitors in cancer treatment

Prof Robert Gilbert, STRUBI

Prof Chris Norbury, Dunn School of Pathology

Prof Geoff Higgins, Department of Oncology
Development of improved inhibitors of cytoplasmic uridylyl transferases implicated in multiple types of cancer, including those of unmet need

Dr Eleftheria Dafni Pefani, Dr Eric O’Neill, Department of Oncology
Uncovering the crosstalk between RASSF1A and BLM to target cancer

Dr Yvonne Couch, RDM
Real-time electrical impedance assessment of barrier permeability responses to inflammatory mediators

Dr Catrine Johansson, Department of Chemistry
Structural and functional characterisation of the histone demethylase JMJD1C a potential therapeutic drug target in leukaemia

Dr Judith Nicholson, Prof Anne Kiltie, Department of Oncology
Mapping and validating clinically significant acetylation modifications in the DNA damage response pathway related to radiosensitisation mechanisms

Prof Stephen Faulkner, Department of Chemistry

Dr Bart Cornelissen, Dr Rebekka Hueting, Department of Oncology
Novel 89Zr chemistry for molecular imaging

Dr Lynn Quek, RDM
Lentiviral Barcoding of Primary Human AML Stem Cells

Dr Michael Holmes, Prof Zhenhming Chen, CTSU
Using novel metabolomics profiling for improved risk prediction and understanding of aetiology of pancreatic cancer

Dr Mariolina Salio, Prof Enzo Cerundolo, MRC Human Immunology Unit
Analysis of the T Cell repertoire in bladder cancer

Dr Ronan Broderick, Department of Oncology
Exploiting the potential on a novel human exonuclease required for homologous recombination in cancer therapy

Dr Richard Hopkinson, Department of Chemistry
Investigating the Molecular Mechanisms of Formaldehyde-induced Carcinogenicity

Prof Richard Gibbons, Dr Dennis Ptchelkine, WIMM
Determining the structure of the ATRX tumour suppressor complex

Dr Omer Dushek, Sir William Dunn School of Pathology
Phenotypic models of chimeric antigen receptors for cancer therapy

Dr Tim Humphrey, CRUK / MRC Oxford Institute for Radiation Oncology
Determinants of histone H3K36Me3 loss and tumorigenesis

Dr Bostjan Markelc, CRUK / MRC Oxford Institute for Radiation Oncology
Understanding the blood flow and sprouting angiogenesis in tumours via a multidisciplinary approach based on mathematical modelling and 3D in vivo imaging

Dr Valentine Macaulay, Dr Tamara Aleksic, Department of Oncology
Investigating the clinical-translational significance of nuclear IGF-1R

Prof Peter McHugh, Department of Oncology

Prof Jan Rehwinkel, Weatherall Institute of Molecular Medicine

Prof Adrian Harris, Department of Oncology
Investigating how the therapeutic DNA damage induces and antiviral state and the role of CDK8, a druggable kinase, in mediating this process

Dr James Franklin, CRUK & EPSRC Cancer Imaging Centre in Oxford
Genomic characterisation of imaging phenotypes in colorectal liver metastases

Dr Fiona Larner, Department of Earth Sciences
High Precision Zinc Isotopic Compositions in Breast Cancer

Dr Michael McDonough, Department of Chemistry
Hypoxia-Inducible Factor-Independent Roles of the Major Kidney Tumour Suppressor von Hippel-Lindau Protein

Dr Clare Verrill, Nuffield Department of Surgical Sciences
Evolution of prostatic adenocarcinoma to neuroendocrine (small cell) carcinoma after hormonal or radiotherapy as a therapy resistance mechanism: a pilot next generation sequencing and immunohistochemical study

Dr Katarzyna Leszczynska, Prof Ester Hammond, CRUK / MRC Oxford Institute for Radiation Oncology
Investigation of hypoxia-regulated p53 function in cancer through its novel downstream target, LGR6

Dr Martin Cohn, Department of Biochemistry
The Fanconi Anemia FANCD2/FANCI protein complex as a potential therapeutic cancer target

Dr Whitney Kellett, Prof James McCullagh, Department of Chemistry
Supercritical fluid chromatography-mass spectrometry metabolomics of glioblastoma

Prof Panagis Filippakopoulos, Structural Genomics Consortium 
ZMYND8-regulation of MITF as potential therapeutic target in melanoma

Dr Eric O’Neill, Department of Oncology

Dr Szele, Department of Physiology, Anatomy & Genetics
Degregulation of Neuronal Stem Cells and Glioma Development

Dr Samantha Hughes, Dr Aziz Aboobaker, & Dr Nobu Kosaka Department of Zoology
An Invertebrate Model to Investigate the Molecular Mechanisms Regarding Sensitivity to Radiation

Dr Roman Fischer & Dr Matthew Cockman, Nuffield Department of Clinical Medicine

Dr Sarah Larkin Nuffield Department of Clinical Neurosciences
Defining the Deep Hypoxia Proteome in Cancer – a Space & Tissue Resolved Case Study on Brain Tumours

Professor Michael Chappell Institute of Biomedical Engineering
DoxCEST:Non-invasive monitoring of targeted chemotherapeutic doxorubicin delivery using Chemical Exchange Saturation Transfer MRI

Dr Su Yin Lim & Professor Ruth Muschel CRUK / MRC Oxford Institute for Radiation Oncology
Angiopoietin-like protein 7 (ANGPTL7) expression in colorectal cancer liver metastasis

Dr Sarah Wordsworth & Dr Paul Hewitson Nuffield Department of Population Health
Could adding genetics to the Bowel Cancer Screening Programme be an acceptable and cost-effective option for the NHS?

Professor Fiona Powrie, Ms Sarah McCuaig, Dr Nathan West Kennedy Institute

Professor Tim Maughan Department of Oncology
IL-22 signalling and KRAS mutation synergize to promote malignancy and poor prognosis in colorectal cancer

Dr Madalena Tarsounas CRUK / MRC Oxford Institute for Radiation Oncology
Targetting BRCA2 deficiency with GSK3 inhibitors